379 related articles for article (PubMed ID: 18949058)
1. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
4. Anticancer therapy: boosting the bang of Bim.
Hendrickson AW; Meng XW; Kaufmann SH
J Clin Invest; 2008 Nov; 118(11):3582-4. PubMed ID: 18949061
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
6. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
8. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.
VanBrocklin MW; Verhaegen M; Soengas MS; Holmen SL
Cancer Res; 2009 Mar; 69(5):1985-94. PubMed ID: 19244105
[TBL] [Abstract][Full Text] [Related]
10. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
[TBL] [Abstract][Full Text] [Related]
12. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway.
Craxton A; Draves KE; Gruppi A; Clark EA
J Exp Med; 2005 Nov; 202(10):1363-74. PubMed ID: 16301744
[TBL] [Abstract][Full Text] [Related]
13. Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression.
Lutz C; Mozaffari M; Tosevski V; Caj M; Cippà P; McRae BL; Graff CL; Rogler G; Fried M; Hausmann M
Clin Exp Immunol; 2015 Aug; 181(2):343-56. PubMed ID: 25845418
[TBL] [Abstract][Full Text] [Related]
14. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Shao Y; Aplin AE
Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545
[TBL] [Abstract][Full Text] [Related]
15. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
16. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
Aranovich A; Liu Q; Collins T; Geng F; Dixit S; Leber B; Andrews DW
Mol Cell; 2012 Mar; 45(6):754-63. PubMed ID: 22464442
[TBL] [Abstract][Full Text] [Related]
17. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
Deng J; Carlson N; Takeyama K; Dal Cin P; Shipp M; Letai A
Cancer Cell; 2007 Aug; 12(2):171-85. PubMed ID: 17692808
[TBL] [Abstract][Full Text] [Related]
18. Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Boisvert-Adamo K; Aplin AE
Oncogene; 2008 May; 27(23):3301-12. PubMed ID: 18246127
[TBL] [Abstract][Full Text] [Related]
19. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.
Gillings AS; Balmanno K; Wiggins CM; Johnson M; Cook SJ
FEBS J; 2009 Nov; 276(21):6050-62. PubMed ID: 19788418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]